ALX 0646

Drug Profile

ALX 0646

Alternative Names: ALX 646

Latest Information Update: 12 Dec 2003

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NPS Allelix
  • Class Antimigraines
  • Mechanism of Action Serotonin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Migraine

Most Recent Events

  • 12 Dec 2003 Discontinued - Phase-I for Migraine in United Kingdom (PO)
  • 12 Mar 2002 Forest returned all rights to ALX 0646 to NPS
  • 12 Nov 2001 NPS Allelix has received a milestone payment from Forest
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top